[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"screening-tool\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:screening-tool":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,76,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100644187","improving-affordability-in-cancer-care-through-economic-screening-and-support-i-access-100644187",false,"NCT07664436","Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS)","I-ACCESS","Inclusion Criteria:\n\n* Patients: Treatment for cancer at study site, over age 18 years, speak\u002Fread English or Spanish; Caregivers: Identified caregiver of a patient with cancer offered financial hardship screening, over age 18 years, speak\u002Fread English or Spanish; Staff\u002FClinicians: Involvement with I-ACCESS pilot implementation; over age 18 years, speak\u002Fread English or Spanish\n\nExclusion Criteria:\n\n* Unable to read of speak English or Spanish\n* Under the age of 18 years old","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","Screening and referral program to proactively identify financial hardship in adult patients with cancer and connect those at-risk with education, counseling, and resources. Patients with cancer will be screened as part of routine care and referred to available resources at their institution, following the referral processes developed and mapped in Aim 1.",[26,27,28,29],"Cancer","Financial Burden","Financial Toxicity","Screening Tool","NOT_YET_RECRUITING","2026-06-17",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":20},"2027-09-01",{"date":38,"type":20},"2029-09-01",{"name":40,"class":41},"UNC Lineberger Comprehensive Cancer Center","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100638156","focus-bipolar-families-opening-conversations-for-understanding-signs-100638156","NCT07622927","FOCUS Bipolar: Families Opening Conversations for Understanding Signs","A Data-Driven Approach to Early Mental Health Screening in Offspring of Parents With Bipolar Disorder","FOCUS Bipolar","Inclusion Criteria for Group A - Parent with Bipolar Disorder:\n\n1. Age: 18 years or older.\n2. Confirmation of a lifetime Bipolar I or II diagnosis\n3. Parent status: Has at least one biological child aged 7-21 years.\n4. Capacity and willingness to consent: Able and willing to provide informed consent.\n5. Study participation: Able to comply with study procedures (e.g., co-design sessions, interviews, assessments).\n6. Language: Able to read, speak, and understand English.\n\nInclusion Criteria for Group B - Adult Caregiver:\n\n1. Age: 18 years or older.\n2. Caregiver status: The adult primarily responsible for the daily care and\u002For medical decisions for ≥ 6 months for a child aged 7-21 years whose biological parent has a lifetime, clinician-confirmed diagnosis of Bipolar I or II disorder.\n3. Capacity and willingness to consent: Able and willing to provide informed consent.\n4. Study participation: Able to comply with study procedures (e.g., co-design sessions, interviews, assessments).\n5. Language: Able to read, speak, and understand English.\n\nInclusion Criteria for Group C - At-Risk Youth:\n\n1. Age:\n\n   1. Phase 1 (co-design) and Phase 2A (alpha testing): 13-18 years\n   2. Phase 2B (beta testing): 13-18 years\n   3. Phase 3 (screening): 7-21 years\n2. Diagnosis status: Must not have a current diagnosis of Bipolar I or II disorder.\n3. Parental diagnosis: Has at least 1 biological parent with a lifetime, clinician-confirmed Bipolar I or II diagnosis (as defined in Groups A and B).\n4. Consent\u002FAssent:\n\n   1. For youth aged 18-21: Able and willing to provide informed consent (verbal)\n   2. For youth aged 7-21: Parent\u002Fguardian\u002FLAR able and willing to provide informed consent (verbal) and youth able to provide assent (verbal)\n5. Participant ability: Able and willing to participate in study activities (e.g., co-design discussions, questionnaires, or screening assessments.\n6. Language: English sufficient to comprehend study procedures and materials.\n\nCriteria for Exclusion of Participants\n\nA potential participant will NOT be eligible for participation in this study if any of the following criteria are met:\n\n1. Unable to provide informed consent due to cognitive impairment or language barriers\n2. Experiencing acute psychiatric instability at enrollment (e.g., acute psychosis or acute suicidality without stabilization)\n3. Has a medical or psychiatric condition that, in the judgment of the Principal Investigator or study clinician, would place undue risk on the individual or interfere with standard clinical care",true,"7 Years",{"count":53,"type":20},200,"OBSERVATIONAL","Bipolar disorder often runs in families, but early symptoms in youth can go unrecognized for years. This project evaluates a structured, family-centered approach to informed screening for youth ages 7-21 who have a biological parent with bipolar disorder.\n\nThe main questions addressed by this project are:\n\nWhether a co-designed video decision aid improves caregiver understanding of bipolar disorder genetic risk and supports informed decisions about youth screening.\n\nWhether remote mental health screening tools are feasible and acceptable for youth with familial risk for bipolar disorder.\n\nWhether screening results can be used to identify early risk patterns and inform tailored follow-up recommendations.\n\nParticipants may be involved in one or more study activities, including co-design of educational decision-aid content, feedback on decision-aid prototypes, beta testing of the decision aid, and remote youth mental health screening. The study does not assign treatment and does not change existing clinical care or clinic routines.",[57,58,59,29],"Bipolar Disorder (BD)","Bipolar Disorder I or II","Bipolar Disorder Family Members",[61,62,63,64],"bipolar disorder","bipolar I","bipolar II","bipolar disorder screening","RECRUITING","2026-05-27",{"date":68,"type":34},"2026-06-03",{"date":70,"type":34},"2026-03-11",{"date":72,"type":20},"2027-07-31",{"name":74,"class":41},"University of Texas Southwestern Medical Center",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":54,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":75},"100569438","improving-outpatient-endometrial-biopsy-results-100569438","NCT06694246","Improving Outpatient Endometrial Biopsy Results","Outpatient Endometrial Biopsy Results; a Quality Improvement Project.","Inclusion Criteria:\n\n* All patients undergoing outpatient endometrial biopsy in the specified time interval (11\u002F2024- 4\u002F2025) will be included.\n\nExclusion Criteria:\n\n* Could not obtain the sample due to patient physicals, anxiety (patient decline), cervical stenosis, or severe bleeding","FEMALE",{"count":85,"type":20},400,"6 Months","Pipelle is the most commonly used outpatient endometrial biopsy device. Pipelle endometrial biopsy can diagnose 90% of endometrial cancer cases. Pipelle endometrial biopsy is one of the first-line diagnostic procedures for women presenting with abnormal peri- and post-menopausal vaginal bleeding.\n\nInsufficient samples are obtained in 5-23% of cases. In Adan Hospital, a retrospective analysis of all outpatient endometrial samples sent to the histopathology department from April- to October 2024 study showed an insufficient sample percentage of 32% This may be attributed to factors such as patients, equipment, and physicians.\n\nThis project aims to improve the endometrial biopsy results by Identifying these factors in the Adan hospital setting, Implementing measures to modify these factors, and finally re-auditing the endometrial biopsy results after six months.",[89,29,90],"Histopathology","Techniques",[92,93,94,95,96,97],"Pipelle","Endometrial biopsy","histopathology","endometrial sampling","screening","outpatient","2024-12-02",{"date":100,"type":34},"2024-12-04",{"date":102,"type":34},"2024-11-01",{"date":104,"type":20},"2025-04-30",{"name":106,"class":41},"Cairo University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":115,"studyType":54,"phases":4,"briefSummary":116,"conditions":117,"keywords":124,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100567757","clinical-studies-of-endometrial-cytology-and-cervical-methylation-assays-in-endometrial-cancer-screening-and-fertility-preservation-evaluation-100567757","NCT06672341","Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation","A Prospective, Open, Observational Clinical Study on Endometrial Cytology and Cervical Methylation Testing for Screening and Evaluating Fertility-Sparing Treatment in Endometrial Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for the study:\n\n  1. Color Doppler ultrasound indicating intrauterine masses or abnormal endometrial thickening (for postmenopausal women not receiving hormone replacement therapy, endometrial thickness \\>5mm).\n  2. Patients undergoing follow-up and efficacy evaluation for fertility-sparing treatment of endometrial cancer or atypical endometrial hyperplasia.\n  3. Patients with endometrial thickening following endocrine therapy for breast cancer.\n  4. Signed informed consent form.\n  5. Good compliance.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Diagnosed with cervical cancer.\n  2. Severe systemic complications preventing hysteroscopy.\n  3. Pregnant or recent history of miscarriage.\n  4. Acute genital tract infection or pelvic inflammatory disease.\n  5. Insertion of an intrauterine device.\n  6. Sexual activity, vaginal douching, or medication use within 24 hours.",{"count":53,"type":20},"1 Year","The current study aims to assess high-risk patients using both liquid-based cytology and cervical methylation testing. The results will be compared with the traditional hysteroscopic pathological findings to determine the sensitivity and specificity of these methods for early detection of endometrial cancer, thereby evaluating their potential application in early screening.\n\nPrimary Objectives：\n\n1. To evaluate the sensitivity, specificity, and accuracy of endometrial cytology for screening endometrial cancer.\n2. To assess the sensitivity, specificity, and accuracy of methylation testing for screening endometrial cancer.\n3. To perform further molecular testing on tissue samples obtained from endometrial cytology and cervical methylation tests, aiming to explore early screening-sensitive indicators.\n\nSecondary Objectives：\n\n1. To determine the value of endometrial cytology in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.\n2. To assess the value of methylation testing in evaluating the efficacy of fertility-sparing treatments for endometrial cancer.",[118,119,120,121,29,122,123],"Endometrial Cancer","Methylation","Cytology","Fertility Preservation","Liquid Biopsy","Non-invasive",[118,96,125,120,126,127,128,129,130],"methylation","Liquid-Based Cytology Test","Early diagnosis","fertility-sparing","liquid biopsy","non-invasive","2024-11-03",{"date":133,"type":34},"2024-11-05",{"date":135,"type":20},"2024-11-04",{"date":137,"type":20},"2026-02-01",{"name":139,"class":41},"Yulan Ren"]